Health Care & Life Sciences » Biotechnology | Genetic Technologies Ltd.

Genetic Technologies Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
10,134.50
8,810.20
8,459.00
8,403.80
5,463.90
Depreciation, Depletion & Amortization
338.40
232.20
390.10
371.60
303.70
Other Funds
-
-
-
295.10
-
Funds from Operations
9,436.30
9,996.00
7,671.20
7,244.40
5,685.90
Changes in Working Capital
1,550.80
305.10
55.60
430.70
64.60
Net Operating Cash Flow
10,987.10
9,690.90
7,726.80
6,813.60
5,621.30
Capital Expenditures
47.90
192.60
303.50
234.80
2.40
Sale of Fixed Assets & Businesses
-
2,158.00
7.10
52.70
-
Purchase/Sale of Investments
463.30
-
-
-
-
Net Investing Cash Flow
232.40
1,965.40
296.30
182.10
2.40
Issuance/Reduction of Debt, Net
5,581.50
2,150.00
-
-
-
Net Financing Cash Flow
11,923.00
22,867.30
1.70
7,110.00
10.00
Net Change in Cash
1,109.80
15,510.90
7,161.70
191.40
5,501.20
Free Cash Flow
11,035.00
9,883.50
8,030.30
7,048.40
5,623.70
Net Assets from Acquisitions
162.60
-
-
-
-
Change in Capital Stock
6,341.50
20,717.30
1.70
6,814.90
10.00
Exchange Rate Effect
58.50
369.10
863.20
305.70
132.40
Other Uses
20.50
-
-
-
-

About Genetic Technologies

View Profile
Address
60-66 Hanover Street
Fitzroy Victoria (VIC) 3065
Australia
Employees -
Website http://www.gtgcorporate.com
Updated 07/08/2019
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.